Gujarat Inject Peer Comparison

BSE: 524238

₹11.57

₹-0.60 (-4.93%)

As on 28-Aug-2026IST

Market cap

₹169 Cr

Revenue (TTM)

₹46 Cr

P/E Ratio

56.6

P/B Ratio

12.9

Div. Yield

0 %

Edit

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	169	35,497	29,798	16,589	15,507
Revenue (₹ Cr)	46	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	2.99	1,018.97	497.77	603.02	270.18
Net Margin (%)	6.43	10.47	20.72	22.63	23.29
RoE (%)	27.23	21.30	28.49	19.61	14.45
Price to Earnings	56.63	35.10	59.86	27.51	56.31
Price-To-Book	12.95	6.77	14.74	4.76	7.48

Income Statement (₹ Cr)

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	46.35	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	46.55	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	42.46	7,739.53	1,608.91	1,753.71	720.01
EBITDA	3.90	1,943.92	762.90	836.69	388.38
Depreciation	0.00	425.10	98.11	78.88	74.78
EBIT	3.90	1,518.82	664.79	757.81	313.60
Interest	0.00	148.45	26.33	5.43	0.26
Other Income	0.20	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	4.09	1,389.91	669.26	800.55	361.56
Provision for Tax	1.10	370.94	171.48	197.53	91.39
Profit after Tax	2.99	1,018.97	497.77	603.02	270.18

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	11.83	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	0.00	723.57	345.47	142.73	50.51
Current Liabilities	24.84	3,912.24	710.20	508.04	169.08
Total Liabilities	8.69	7,709.37	1,832.56	3,528.05	1,700.71

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	25.10	3,392.16	1,290.62	1,321.38	957.22
Current Assets	11.56	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	8.69	7,709.37	1,832.56	3,528.05	1,700.71
Total Debt*	0.00	2,072.49	82.51	0.00	6.23
Net Current Assets	-13.27	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	--	285.51	27.73	4.82	14.31

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-6.03	1,097.24	261.18	413.52	265.47
Cash Flow from Investing Activities	0.00	-712.51	-149.69	-116.48	-154.61
Cash from Financing Activities	8.88	-164.21	-69.28	-279.44	-99.21
Net Cash Inflow / Outflow	2.86	220.52	42.21	17.59	11.64

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	2.54	19.87	33.51	28.31	29.13
ROE (%)	27.23	21.30	28.49	19.61	14.45
ROA (%)	12.31	11.42	19.48	16.31	12.66
EBIT Margin (%)	8.41	15.68	28.03	29.25	28.29
Net Margin (%)	6.43	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	1.43	0.00	0.00	0.00	0.00

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	151.64	18.36	78.33	7.93	-6.72
EBIT Growth (%)	286.99	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	209.51	32.39	182.61	21.66	-24.38
EPS Growth (%)	92.99	36.68	277.72	25.42	-21.99
Book Value Growth (%)	775.00	18.16	29.06	8.90	18.34

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	9.08	34.38	59.86	26.64	55.82
Price / Book Value	12.95	6.77	14.74	4.76	7.48
Dividend Yield (%)	0.00	0.19	0.15	0.37	0.51
EV/EBITDA	42.74	18.51	38.85	18.89	38.86
Market Cap (₹ Cr)	11.24	0.00	8,058.80	9,499.31	15,922.01

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	--	0.32	--	--	--
Current Ratio	0.47	1.43	2.09	5.21	7.39
Quick Ratio	0.47	0.82	1.37	3.85	5.46
Interest Coverage	237.71	10.36	26.41	148.49	1,386.30

	Gujarat Inject	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	13.69	26.46	22.82	41.42	41.52
Asset Turnover	1.91	1.09	0.93	0.70	0.52
Receivable days	0.00	94.32	86.10	125.30	111.87
Inventory Days	0.00	78.21	73.73	101.28	75.42
Payable days	14.62	193.72	114.75	149.95	149.88
Cash Conversion Cycle	-14.62	-21.19	45.08	76.63	37.41

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.